A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Inclusion Criteria:

1. Histologically diagnosed high-grade serous or endometrioid recurrentovarian,fallopian tube,or peritoneal cancer.

2. Patients must have received at least 2 previous platinum-containing regimens.

3. At least one target lesion.

4. ECOG performance status 0-1.

5. Adequate bone marrow, kidney and liver function.

Exclusion Criteria:

1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib.Forexploratory cohort ，patients who received PARP inhibitor are eligible;

2. Prior malignancy unless curatively treated and disease-free for > 5 years prior tostudy entry. Prior adequately treated non-melanoma skin cancer, in situ cancer ofthe cervix allowed;

3. Radiation or anti-hormonal therapy or anticancer therapy within 14 days before firstadministration;

4. Known to be human immunodeficiency virus positive;

5. Known active hepatitis C virus, or known active hepatitis B virus;

6. Untreated and/or uncontrolled brain metastases;

7. Patients with clinical symptoms of cancer ascites, pleural effusion, who need todrainage, or who have undergone ascites drainage within 3 months prior to the firstadministration;

8. Pregnant or breast-feeding women.